PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$90.37
as of March 26, 2025 -
YTD RETURNS4.70%
as of March 26, 2025 -
Total Net Assets$667.68M
as of March 26, 2025 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Fund Description
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Fund Highlights
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
Performance
Fees
Holdings
Portfolio
Sector Weightings (%) as at 02/28/2025
-
Sector
% of Net Assets -
Health Care
99.77 -
Other/Cash
0.23
Country Weightings (%) as at 02/28/2025
-
Country
% of Net Assets -
United States
60.94 -
United Kingdom
14.63 -
Denmark
6.50 -
Switzerland
5.27 -
France
4.90 -
Japan
4.59 -
Israel
2.94 -
Other/Cash
0.23